PMID- 12798711
OWN - NLM
STAT- MEDLINE
DCOM- 20030627
LR  - 20231213
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 89
IP  - 3
DP  - 2003 Jun
TI  - Expression of matrix metalloproteinase-26 and tissue inhibitors of 
      metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer.
PG  - 453-9
AB  - OBJECTIVE: Matrix metalloproteinases (MMPs) and their physiological inhibitors, 
      the tissue inhibitors of MMPs (TIMPs), play a key role in tumor cell invasion, 
      angiogenesis, and growth. The aim of this study was to determine the expression 
      and cellular distribution of MMP-26, TIMP-3, and TIMP-4 in endometrial cancers 
      and benign endometrium throughout the menstrual cycle and the correlation with 
      tumor histological subtype, stage, and grade. METHODS: Immunohistochemical 
      analysis using polyclonal antibodies generated against pro- and active MMP-26, 
      and mono- and polyclonal antibodies specific to TIMP-3 and TIMP-4, respectively, 
      was performed. RESULTS: MMP-26, TIMP-3, and TIMP-4 are expressed in endometrial 
      carcinomas (N = 86) and benign endometrium (N = 50) from various stages of the 
      menstrual cycle. Semi-quantitative analysis of staining intensity indicated that 
      endometrial carcinomas expressed more MMP-26, TIMP-3, and TIMP-4 compared to 
      benign endometrium from the postmenopausal period, but not from the secretory 
      phase of the menstrual cycle. The highest staining intensity was associated with 
      endometrial epithelial cells, followed by vascular endothelial cells, myometrial 
      smooth muscle cells, and endometrial stromal cells. Increased staining intensity 
      of MMP-26 and TIMP-3 correlated with grade III tumors and MMP-26 and TIMP-4 with 
      the depth of myometrial invasion in tumors histologically characterized as 
      endometrioid adenocarcinoma, clear-cell, and papillary serous carcinoma 
      staged/graded based on FIGO criteria. CONCLUSION: MMP-26 and TIMP-4 are expressed 
      in endometrium and endometrial carcinoma and their elevated expression and 
      correlation with myometrial invasion suggests that MMP-26 and TIMP-4 may play a 
      key role in endometrial tumor progression.
FAU - Tunuguntla, Renuka
AU  - Tunuguntla R
AD  - Department of Obstetrics/Gynecology, University of Florida, Gainesville, FL 
      32610, USA.
FAU - Ripley, Daylene
AU  - Ripley D
FAU - Sang, Qing Xiang Amy
AU  - Sang QX
FAU - Chegini, Nasser
AU  - Chegini N
LA  - eng
GR  - CA78646/CA/NCI NIH HHS/United States
GR  - HD37432/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Tissue Inhibitor of Metalloproteinase-3)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - EC 3.4.24.- (MMP26 protein, human)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - EC 3.4.24.- (Matrix Metalloproteinases, Secreted)
SB  - IM
MH  - Adenocarcinoma, Clear Cell/enzymology/metabolism/pathology
MH  - Carcinoma, Endometrioid/enzymology/metabolism/pathology
MH  - Cystadenocarcinoma, Papillary/enzymology/metabolism/pathology
MH  - Endometrial Neoplasms/enzymology/*metabolism/pathology
MH  - Endometrium/enzymology/metabolism
MH  - Epithelial Cells/enzymology/metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Matrix Metalloproteinases/*biosynthesis
MH  - Matrix Metalloproteinases, Secreted
MH  - Tissue Inhibitor of Metalloproteinase-3/*biosynthesis
MH  - Tissue Inhibitor of Metalloproteinases/*biosynthesis
MH  - Tissue Inhibitor of Metalloproteinase-4
EDAT- 2003/06/12 05:00
MHDA- 2003/06/28 05:00
CRDT- 2003/06/12 05:00
PHST- 2003/06/12 05:00 [pubmed]
PHST- 2003/06/28 05:00 [medline]
PHST- 2003/06/12 05:00 [entrez]
AID - S0090825803000775 [pii]
AID - 10.1016/s0090-8258(03)00077-5 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2003 Jun;89(3):453-9. doi: 10.1016/s0090-8258(03)00077-5.